glp 1 and celiac disease Association between autoimmune diseases glucagon-like peptide-1 receptor agonists: A real-world evidence study GLP-1 Agonists, Gut Microbiome Dysbiosis

[1] [6] Patients should be advised to seek immediate medical attention for severe abdominal pain, persistent vomiting, signs of dehydration, allergic reactions, or visual changes while taking Rybelsus

Considerations to remember when prescribing somatostatin analogues to patients are that (1) gallbladder motility is diminished and up to 30% of patients develop gallbladder stones,55,57 and (2) inhibition of pancreatic enzyme secretion and of fat malassimilation/malabsorption may occur, resulting in steatorrhea.55,58 Didden et al55 found that steatorrhea was significantly higher during short-acting compared to long-acting somatostatin analogues

You may have witnessed the excitement surrounding the new classes of medications being used for weight loss: GLP-1 receptor agonists, like Wegovy and Ozempic, and the newer, dual action (GLP1/GIP) medications like Mounjaro and Zepbound

Tirzepatide shortage resolution followed a similar timeline

(2001) Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

Your treatment goals and expectations should be clearly established